Related Experiment Video
Updated: Jun 13, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Infusion fluids contain harmful glucose degradation products
Anna Bryland1, Marcus Broman, Martin Erixon
1Department of Nephrology, Lund University, Lund, Sweden.
Intensive Care Medicine
|April 17, 2010
Summary
Standard glucose infusion fluids contain harmful glucose degradation products (GDPs) that increase in patients
Area of Science:
- Biochemistry
- Cell Biology
- Clinical Medicine
Background:
- Glucose degradation products (GDPs) are precursors to advanced glycation end products (AGEs), contributing to cellular damage and inflammation.
- Commercially available glucose-containing infusion fluids are a potential source of GDPs.
Purpose of the Study:
- To quantify GDPs in glucose infusion fluids.
- To determine if GDPs are present in patients receiving glucose infusions.
- To assess the impact of heat-sterilized fluids on cellular functions.
Main Methods:
- High-performance liquid chromatography (HPLC) was used to analyze GDP content in infusion fluids.
- Blood samples from patients receiving glucose fluids (n=11) and controls (n=11) were analyzed for GDPs and carboxymethyllysine (CML).
- Cell viability, cytokine secretion, and microbial killing were assessed in response to tested fluids.
Main Results:
- All tested glucose fluids contained high GDP concentrations, including 3-deoxyglucosone (3-DG).
- Patients receiving glucose infusions showed an eight-fold increase in serum 3-DG and elevated CML levels, correlating with infused 3-DG.
- Infusion fluids damaged neutrophils, reducing cytokine secretion and microbial killing capacity.
Conclusions:
- Standard fluid therapy with glucose infusions introduces significant amounts of GDPs.
- Reducing GDP content in infusion fluids may enhance cell and organ function, particularly in intensive care settings.
Related Concept Videos
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:24Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...